Pacira Pharma (PCRX) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
February 28, 2023 8:00 AM ESTRecord revenues of $667 million in 2022
Full-year GAAP net income of $16 million and adjusted EBITDA of $213 million
EXPAREL surpasses the 12 million patient mark
Conference call today at 8:30 a.m. ET
TAMPA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2022.
2022 was a solid year for Pacira as we posted record revenue and significant... More
